Investigation the effect of probiotics in patients with COVID-19

The effect of probiotics as an adjunctive therapy with mortality outcome, length and rate of hospitalization in Intensive Care Unit in patients with COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220124053820N1

Enrollment

Registered

2022-09-19

Start date

2022-09-06

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: The intervention group receives probiotic Lactocare 500 mg capsules produce by Zist Takhmir company twice a day in addition to the treatment prescribed by the infectious disease speci

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who are hospitalization due to COVID-19. Patients should be 18 years old and older. Patients should have clinical symptoms and pneumonia of covid in chest radiography or CT scan. Patients should not particitaion in other clinical trials at the same time.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Need to admission to ICU. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Need to intubation. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Mortality. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Vital signs. Timepoint: Three times a day. Method of measurement: By evaluator using mercury sphygmomanometer and t?ermometer.;Symptoms consisting cough, dyspnea, diarrhea, abdominal pain. Timepoint: Daily. Method of measurement: By evaluator asking patient and patient's file.;O2 saturation. Timepoint: Three times a day. Method of measurement: By evaluator using pulse oxymeter.;Laboratories tests: Hb, Platelet, ESR, CRP, WBC, lymphocyce, NLR, CPK, ALT, AST, fibrinogen, D-dimer. Timepoint: Daily. Method of measurement: By Razi Hospital Laboratory.;Length of hospitalization. Timepoint: Daily. Method of measurement: By evaluator by pstient's file.	—

Measure

Time frame

Need to admission to ICU. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Need to intubation. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Mortality. Timepoint: Daily. Method of measurement: By evaluator using patient's file and ward's information.;Vital signs. Timepoint: Three times a day. Method of measurement: By evaluator using mercury sphygmomanometer and t?ermometer.;Symptoms consisting cough, dyspnea, diarrhea, abdominal pain. Timepoint: Daily. Method of measurement: By evaluator asking patient and patient's file.;O2 saturation. Timepoint: Three times a day. Method of measurement: By evaluator using pulse oxymeter.;Laboratories tests: Hb, Platelet, ESR, CRP, WBC, lymphocyce, NLR, CPK, ALT, AST, fibrinogen, D-dimer. Timepoint: Daily. Method of measurement: By Razi Hospital Laboratory.;Length of hospitalization. Timepoint: Daily. Method of measurement: By evaluator by pstient's file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shadi dehghanzadeh

Rasht Islamic Azad University

shadidehghan90@gmail.com+98 54 9194 1476

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026